Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...

The U.S. Food and Drug Administration have approved GlaxoSmithKline’s Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive ...

BioWorld - Tuesday, November 21, 2023 See today's BioWorld Home » Anoro Ellipta Briefing Docs Promising Ahead of PADAC Meeting Subscribe to BioWorld™ news services See subscription options To read the ...

Please provide your email address to receive an email when new articles are posted on . Outcomes may vary among different fixed-dose combination inhalers for COPD ...

Adherium, a New Zealand-based maker of connected respiratory medical devices, has received the US Food and Drug Administration's 510(k) clearance for connecting its digital monitoring platform with ...

Check this table to make sure you can use your COPD inhalers together ...

GSK plc GSK announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rivals AstraZeneca AZN and Boehringer ...

Umeclidinium 62.5mcg, vilanterol 25mcg; per ­inhalation; dry pwd for oral inhalation. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in ...